The 49 most recent market catalysts affecting $PFE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Bullish
Impact 65
Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases
Pfizer has secured an exclusive licensing agreement with Starna Therapeutics for three pre-IND CAR-T programs focused on autoimmune diseases, excluding Greater China. This move is …
Nov 14, 2026
Corporate Catalyst
Neutral
Impact 75
Pfizer GLP-1 Medications Included in China's National Health Insurance
Pfizer's GLP-1 medications, along with those from Innovent, have been included in China's national health insurance program for diabetes. This is a significant positive development…
Nov 13, 2026
Corporate Catalyst
Bullish
Impact 65
Pfizer's Talzenna Receives Positive EU Opinion for HRR-Mutated Prostate Cancer
Pfizer announced that its drug Talzenna received a positive opinion from the European Medicines Agency's CHMP for expanded use in adults with homologous recombination repair (HRR) …
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 75
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
Pfizer announced a strategic co-funding agreement with Blackstone Life Sciences, where Blackstone will provide up to $1.5 billion to fund the development of berobenatide, an invest…
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 75
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
Pfizer has entered into a strategic funding agreement with Blackstone Life Sciences, securing up to $1.5 billion to advance its obesity drug candidate, berobenatide. This is signif…
Nov 11, 2026
Market Technicals
Bullish
Impact 55
Daiwa Securities Adjusts Price Target on Pfizer to $29 From $27
Daiwa Securities adjusted its price target for Pfizer Inc. upwards from $27 to $29 on November 11, 2026. This analyst action indicates a revised, more favorable valuation outlook f…
Nov 7, 2026
Corporate Catalyst
Bullish
Impact 55
Freedom Broker Raises Pfizer Price Target to $34
Freedom Broker, an analyst firm, has raised its price target for Pfizer (PFE) to $34, up from $33, and maintained a 'Buy' rating. This indicates a continued positive sentiment from…
Nov 6, 2026
Corporate Catalyst
Bearish
Impact 55
DZ Bank Downgrades Pfizer to Hold From Buy
DZ Bank, a significant financial institution, has downgraded Pfizer's stock rating from 'Buy' to 'Hold' and established a new price target of $33. This action indicates a more cons…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 65
Pfizer CEO Outlines Strategy for Obesity Drug Market Entry
Pfizer's CEO, Albert Bourla, has publicly articulated the company's strategic entry into the lucrative obesity drug market. This involves leveraging berobenatide, an asset from the…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 65
Analysts Adjust Price Targets for Pfizer Following Third-Quarter Results
Following Pfizer's third-quarter 2026 financial results, analysts from Morgan Stanley, RBC, and UBS updated their price targets. Morgan Stanley lowered its target, indicating a mor…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 85
Pfizer Reports Third-Quarter 2026 Financial Results and Raises Full-Year Guidance
Pfizer announced robust third-quarter 2026 financial results, which led to an upward revision of its full-year 2026 guidance for both total revenues and adjusted diluted earnings p…
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 55
Pfizer Appoints Cecile Guegan as Chief Financial Officer
Pfizer Inc. has officially appointed Cecile Guegan as its Chief Financial Officer and Executive Vice President, effective November 1, 2026. She had been serving as interim CFO sinc…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 75
Pfizer Reports Q2 Revenue Growth and Raises Full-Year Outlook
Pfizer's preliminary Q2 results indicate robust performance with an 18% revenue increase year-over-year, excluding currency effects. This positive momentum has led the company to r…
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 75
Pfizer Announces Positive Topline Results from Phase 3 MagnetisMM-32 Study of ELREXFIO
Pfizer announced positive topline results for its ELREXFIO drug in a Phase 3 study for relapsed or refractory multiple myeloma. This is significant because the drug met its primary…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 55
Jefferies Maintains Buy Rating on Pfizer
Jefferies has maintained its 'Buy' rating on Pfizer with a $36 price target, a decision directly influenced by the positive Phase II clinical data from the FOURLIGHT-1 study for me…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 75
European Commission Approves Combination Therapy Involving Pfizer and Astellas
The European Commission has approved the combination therapy of pembrolizumab (Pfizer) and enfortumab vedotin (Astellas) for perioperative treatment, backed by strong Phase 3 data …
Oct 15, 2026
Market Technicals
Bullish
Impact 65
Pfizer Stock Hits 52-Week High: What's Going On?
Pfizer's stock hitting a 52-week high is a significant technical indicator, suggesting strong investor confidence. This move is primarily attributed to two factors: a broad rally a…
Oct 8, 2026
Corporate Catalyst
Bearish
Impact 65
Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’
The Pharmaceutical Research and Manufacturers of America (PhRMA) has sued the Trump administration over its 'most-favored-nation' drug pricing rule, which aims to lower Medicare Pa…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 75
Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease
Pfizer's TUKYSA securing FDA approval for front-line maintenance treatment of HER2-positive metastatic breast cancer is a significant positive development. This expands the drug's …
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 75
Pfizer’s TUKYSA Regimen Obtains FDA Approval As Front-Line Maintenance Treatment For HER2+ Metastatic Breast Cancer
Pfizer announced FDA approval for its drug TUKYSA, in combination with trastuzumab and pertuzumab, as a front-line maintenance treatment for HER2+ metastatic breast cancer. This is…
Oct 5, 2026
Corporate Catalyst
Bearish
Impact 75
Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims
Florida's Attorney General has initiated a lawsuit against Pfizer, accusing the pharmaceutical giant of violating the Florida Deceptive and Unfair Trade Practices Act by misleading…
Oct 2, 2026
Corporate Catalyst
Bullish
Impact 65
Pfizer Announces Its Two Phase 3 Studies Of LITFULO Demonstrate TRANQUILLO 2 and TRANQUILLO, LITFULO Enhance Facial, Total Body Repigmentation Compared To Placebo; Co. Plans To File Data to Regulatory Authorities Globally, Include FDA And European Medicines Agency
Pfizer presented positive results from two Phase 3 trials (TRANQUILLO 2 and TRANQUILLO) for its drug LITFULO (ritlecitinib) in treating nonsegmental vitiligo. The studies showed si…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 75
Pfizer Says Eczema Drug Shows Significant Skin Clearance
Pfizer has released detailed positive Phase 2 results for its novel eczema drug, tilrekimig, showing significant efficacy in clearing skin and reducing itch in patients with modera…
Oct 1, 2026
Corporate Catalyst
Bearish
Impact 65
Florida Attorney General Uthmeier Sues Pfizer Over Alleged Misleading Advertising Of Its COVID Vaccine
The Florida Attorney General has filed a lawsuit against Pfizer, alleging misleading advertising practices concerning its COVID-19 vaccine. This action is significant as it directl…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 75
Pfizer Advances Tilrekimig Into Phase 3 Atopic Dermatitis And Asthma Trials After Phase 2 Study Showed Statistically Significant EASI-75 Gains At Week 16 And No Dose-Dependent Safety Signals
This headline is a significant corporate catalyst for Pfizer, indicating a strong progression in its drug pipeline with a promising candidate, Tilrekimig. The positive Phase 2 resu…
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 55
Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer
Public Citizen, through a FOIA request, has brought to light redacted 'Most Favored Nation' drug pricing agreements signed by the Trump administration with pharmaceutical giants li…
Sep 18, 2026
Macro/Central Bank
Neutral
Impact 75
White House Official Says Trump To Announce All 50 States, DC, And Puerto Rico In Model For Medicaid Drug Pricing Plan
The filing indicates a forthcoming announcement from the Trump administration regarding a new model for Medicaid drug pricing, which will be implemented across all states and terri…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg
The Bloomberg article reports that the FDA's acting drug and vaccine regulators are being considered for permanent roles. This development signals a potential for stability and con…
Aug 31, 2026
Macro/Central Bank
Bullish
Impact 75
Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms
The White House announced a deal with nine pharmaceutical manufacturers to lower drug prices, a significant development in the ongoing debate over healthcare costs. This agreement …
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 55
CNBC Halftime Report Final Trades: Pfizer, Nvidia, Take-Two Interactive Software, Cheniere Energy
The 'CNBC Halftime Report Final Trades' segment often generates short-term trading interest in the featured stocks. While not based on fundamental news or macro shifts, the exposur…
Aug 28, 2026
Geopolitical Risk
Neutral
Impact 55
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
The WHO's decision to maintain the Ebola outbreak in the DRC as a PHEIC, but not elevate it to a pandemic emergency, signifies that while the situation is serious and requires inte…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 55
President Trump Nominates Heidi Overton, MD, PhD, As Next FDA Commissioner
The filing is a social media post from Donald Trump announcing his intention to nominate Heidi Overton as the next FDA Commissioner. This matters because the FDA Commissioner plays…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 65
'Trump Is Interviewing Potential Nominees for FDA Commissioner' - Bloomberg
The filing, a Bloomberg article, reports that Donald Trump is interviewing potential nominees for FDA Commissioner. This matters because the FDA plays a critical role in drug appro…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 85
Pfizer And Valneva's Lyme Disease Vaccine Candidate PF-07307405 Clears EMA Validation Of Marketing Authorization Application After Phase 3 VALOR Trial Showed More Than 70% Efficacy
The EMA validation of the marketing authorization application for PF-07307405 is a crucial regulatory hurdle cleared, bringing Pfizer and Valneva significantly closer to commercial…
Aug 10, 2026
Geopolitical Risk
Neutral
Impact 65
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children
Donald Trump, in a video linked in the filing, stated that a future administration under his leadership would limit recommended childhood vaccinations to 11 core types, specificall…
Aug 6, 2026
Geopolitical Risk
Neutral
Impact 75
'Trump Administration Considers Order on Autism and Vaccines' - Bloomberg
The Bloomberg article indicates that the Trump administration is contemplating an executive order concerning autism and vaccines. This is a significant development because any offi…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide on Weight Loss
Pfizer's Q2 results exceeded analyst expectations for both earnings and revenue, primarily due to strong performance from its non-COVID product portfolio. This positive financial u…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings
Pfizer's strong Q2 earnings, beating both EPS and revenue estimates, served as a significant positive catalyst for the market. This upbeat corporate performance likely instilled in…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
Pfizer Q2 Adj. EPS $0.77 Beats $0.69 Estimate, Sales $15.034B Beat $14.412B Estimate
Pfizer announced its Q2 earnings, revealing adjusted EPS of $0.77 and sales of $15.034 billion, both exceeding analyst expectations. This performance is significant as it demonstra…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 65
Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
The filing details analyst expectations for Pfizer's Q2 earnings, projecting a decrease in both EPS and revenue compared to the prior year. This suggests a challenging quarter for …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Pfizer Announces Topline Results From Two Phase 3 Trials Of LITFULO In Patients With Vitiligo; Both The 50 And 100 Milligram Doses Delivered Significant, Clinically Meaningful Improvements Over Placebo
Pfizer has disclosed successful Phase 3 trial results for LITFULO in treating nonsegmental vitiligo (NSV), showing significant improvements in facial and total body repigmentation.…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out'
The filing centers on Rep. Massie's questioning of Vice President Vance's silence regarding the CDC's $1.24 billion contracts with Pfizer for COVID-19 vaccines, given Vance's prior…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Grants Priority Review For Pfizer's Talzenna sNDA For Men With Homologous Recombination Repair Gene-Altered Metastatic Castration-Sensitive Prostate Cancer
The FDA's Priority Review designation for Pfizer's Talzenna sNDA is a significant positive catalyst for Pfizer, indicating the agency believes the drug could offer a substantial im…
Jul 20, 2026
Corporate Catalyst
Bearish
Impact 55
Pfizer Suspends Popular Menopause Cream in India
Pfizer (PFE) has paused the distribution of its Premarin vaginal cream in India, citing unspecified supply chain issues. This is a significant event for the Indian market, as Prema…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 95
FDA Approves Gedatolisib With Fulvestrant, With Or Without Palbociclib, For Hr-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer
The FDA's approval of Gedatolisib represents a significant development in the treatment of HR-positive, HER2-negative breast cancer. This new therapy, likely from a major pharmaceu…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 55
BMO Capital Maintains Outperform on Pfizer, Lowers Price Target to $30
BMO Capital's decision to lower Pfizer's price target from $34 to $30, while maintaining an 'Outperform' rating, signals a nuanced view. This adjustment likely reflects updated fin…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.